The CATALIS Network: A Public-Private Partnership to Optimize Clinical Research in Quebec for the Benefit of Patients
Our Founding Partners
Since its creation, CATALIS Quebec has relied on the vision and collaboration of key partners from the life sciences sector. The organization wishes to acknowledge the pivotal role of the Quebec Consortium for Drug Discovery (CQDM) and Montreal InVivo in its founding and growth.
In 2015–2016, Montreal InVivo identified the strategic need for Quebec to attract more industry-funded early-phase clinical trials and to position itself on the global clinical research landscape. At their initiative, in 2017, the Quebec Life Sciences Strategy (SQSV) provided funding, and the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE) mandated CQDM to implement this major provincial initiative.
Under the leadership of its President and CEO, Diane Gosselin, CQDM founded the coordination office that gave rise to CATALIS. In 2018, CATALIS became a legal and independent entity. Ms. Gosselin served as its Executive Chair until 2021 and has continued her commitment as a board member since then.
Today, CATALIS’s mission extends to all areas of clinical research. Its Network brings together over 250 experts from the public and private sectors, including patient representatives, all united to advance clinical research in Quebec.
We would like to thank CQDM and Montreal InVivo for their invaluable contribution to the creation of CATALIS Quebec.